Who to call at Recursion Pharmaceuticals, Inc., and when
Fundz watches for the moments Recursion Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day Recursion Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Recursion Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Recursion Pharmaceuticals, Inc.. With Fundz connected, it knows.
Recursion Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
recursion.comAI Executive Summary
AI-powered analysis of 8-K filing content
Recursion Pharmaceuticals named Najat Khan, Ph.D., its CRDO and CCO, as CEO and President, effective January 1, 2026, while Christopher Gibson, Ph.D., steps down from those roles to become Board Chair. The change moves a current senior operating executive into the top job and shifts the founder-CEO to a board role.
Key Takeaways
Najat Khan, Ph.D., currently Chief Research and Development Officer and Chief Commercial Officer, will become CEO and President effective January 1, 2026.
Christopher Gibson, Ph.D., steps down as CEO and President and becomes Chair of the Board, effective the same date.
3 more takeaways
Related Filings (11)
11 more filings from Recursion Pharmaceuticals, Inc. in the last 90 days
Filing Overview
What This Means
Recursion Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.